Proteomic profiling of the tumor microenvironment: Recent insights and the search for biomarkers

Genome Medicine

Volumn 6, Issue 2, 2014, Pages

  Hanash, Sam ^a   Schliekelman, Mark ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; TUMOR MARKER;

CANCER CELL; CANCER DIAGNOSIS; CARCINOGENESIS; CELL INFILTRATION; CELL INTERACTION; CELL POPULATION; CIRCULATION; DISEASE ACTIVITY; EXTRACELLULAR MATRIX; GENE FUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; METASTASIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; STROMA; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

EID: 84894527895     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm529     Document Type: Review

References (91)

1. Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev 2009, 28:113-127. 10.1007/s10555-008-9173-4, 2658728, 19153673.
2. Kass L, Erler JT, Dembo M, Weaver VM. Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. Int J Biochem Cell Biol 2007, 39:1987-1994. 10.1016/j.biocel.2007.06.025, 2658720, 17719831.
3. Pathak A, Kumar S. Independent regulation of tumor cell migration by matrix stiffness and confinement. Proc Natl Acad Sci U S A 2012, 109:10334-10339. 10.1073/pnas.1118073109, 3387066, 22689955.
4. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906. 10.1016/j.cell.2009.10.027, 2788004, 19931152.
5. Zaman MH, Trapani LM, Sieminski AL, Mackellar D, Gong H, Kamm RD, Wells A, Lauffenburger DA, Matsudaira P. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proc Natl Acad Sci U S A 2006, 103:10889-10894. 10.1073/pnas.0604460103, 1544144, 16832052.
6. Miles FL, Sikes RA. Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res 2014, doi:10.1158/1541-7786.MCR-13-0535.
7. Wong GS, Rustgi AK. Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br J Cancer 2013, 108:755-761. 10.1038/bjc.2012.592, 3590656, 23322204.
8. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002, 14:608-616. 10.1016/S0955-0674(02)00361-7, 12231357.
9. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322. 10.1016/j.ccr.2012.02.022, 22439926.
10. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 2011, 13:227. 10.1186/bcr2912, 3326543, 22078026.
11. Xouri G, Christian S. Origin and function of tumor stroma fibroblasts. Semin Cell Dev Biol 2010, 21:40-46. 10.1016/j.semcdb.2009.11.017, 19944178.
12. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011, 11:805-812. 10.1038/nrc3153, 3426440, 22020206.
13. Angel TE, Aryal UK, Hengel SM, Baker ES, Kelly RT, Robinson EW, Smith RD. Mass spectrometry-based proteomics: existing capabilities and future directions. Chem Soc Rev 2012, 41:3912-3928. 10.1039/c2cs15331a, 3375054, 22498958.
14. Simona F, Laura S, Simona T, Riccardo A. Contribution of proteomics to understanding the role of tumor-derived exosomes in cancer progression: state of the art and new perspectives. Proteomics 2013, 13:1581-1594. 10.1002/pmic.201200398, 23401131.
15. Mayne J, Starr AE, Ning Z, Chen R, Chiang CK, Figeys D. Fine tuning of proteomic technologies to improve biological findings: advancements in 2011-2013. Anal Chem 2014, 86:176-195. 10.1021/ac403551f, 24191679.
16. Zhang Q, Faca V, Hanash S. Mining the plasma proteome for disease applications across seven logs of protein abundance. J Proteome Res 2011, 10:46-50. 10.1021/pr101052y, 21062094.
17. Wolters DA, Washburn MP, Yates JR. An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 2001, 73:5683-5690. 10.1021/ac010617e, 11774908.
18. Cardoza JD, Parikh JR, Ficarro SB, Marto JA. Mass spectrometry-based proteomics: qualitative identification to activity-based protein profiling. Wiley Interdiscip Rev Syst Biol Med 2012, 4:141-162. 10.1002/wsbm.166, 3288153, 22231900.
19. Uhlen M, Ponten F. Antibody-based proteomics for human tissue profiling. Mol Cell Proteomics 2005, 4:384-393. 10.1074/mcp.R500009-MCP200, 15695805.
20. Chandra H, Reddy PJ, Srivastava S. Protein microarrays and novel detection platforms. Expert Rev Proteomics 2011, 8:61-79. 10.1586/epr.10.99, 21329428.
21. Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly M, Yang Y, Patel M, Liu X, Thilaganathan N, Larina IV, Dickinson ME, West JL, Gibbons DL, Liu DD, Kim MP, Hicks JM, Wistuba II, Hanash SM, Kurie JM. Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One 2013, 8:e67054. 10.1371/journal.pone.0067054, 3677922, 23785517.
22. Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol 2011, 209:139-151. 10.1530/JOE-10-0377, 21307119.
23. Ong SE, Kratchmarova I, Mann M. Properties of 13C-substituted arginine in stable isotope labeling by amino acids in cell culture (SILAC). J Proteome Res 2003, 2:173-181. 10.1021/pr0255708, 12716131.
24. Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong CH, Wang H, Ungewiss C, Ahn YH, Shin DH, Kurie JM, Hanash SM. Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res 2011, 71:7670-7682. 10.1158/0008-5472.CAN-11-0964, 3419137, 21987723.
25. Little GH, Noushmehr H, Baniwal SK, Berman BP, Coetzee GA, Frenkel B. Genome-wide Runx2 occupancy in prostate cancer cells suggests a role in regulating secretion. Nucleic Acids Res 2012, 40:3538-3547. 10.1093/nar/gkr1219, 3333873, 22187159.
26. Rocco M, Malorni L, Cozzolino R, Palmieri G, Rozzo C, Manca A, Parente A, Chambery A. Proteomic profiling of human melanoma metastatic cell line secretomes. J Proteome Res 2011, 10:4703-4714. 10.1021/pr200511f, 21815687.
27. Mathias RA, Chen YS, Wang B, Ji H, Kapp EA, Moritz RL, Zhu HJ, Simpson RJ. Extracellular remodelling during oncogenic Ras-induced epithelial-mesenchymal transition facilitates MDCK cell migration. J Proteome Res 2010, 9:1007-1019. 10.1021/pr900907g, 19954229.
28. Mathias RA, Wang B, Ji H, Kapp EA, Moritz RL, Zhu HJ, Simpson RJ. Secretome-based proteomic profiling of Ras-transformed MDCK cells reveals extracellular modulators of epithelial-mesenchymal transition. J Proteome Res 2009, 8:2827-2837. 10.1021/pr8010974, 19296674.
29. Lai KK, Shang S, Lohia N, Booth GC, Masse DJ, Fausto N, Campbell JS, Beretta L. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet 2011, 7:e1002147. 10.1371/journal.pgen.1002147, 3121762, 21731504.
30. Vincourt JB, Etienne S, Cottet J, Delaunay C, Malanda CB, Lionneton F, Sirveaux F, Netter P, Plénat F, Mainard D, Vignaud JM, Magdalou J. C-propeptides of procollagens I alpha 1 and II that differentially accumulate in enchondromas versus chondrosarcomas regulate tumor cell survival and migration. Cancer Res 2010, 70:4739-4748. 10.1158/0008-5472.CAN-10-0046, 20460531.
31. Blanco MA, LeRoy G, Khan Z, Alečković M, Zee BM, Garcia BA, Kang Y. Global secretome analysis identifies novel mediators of bone metastasis. Cell Res 2012, 22:1339-1355. 10.1038/cr.2012.89, 3434351, 22688892.
32. Sodek KL, Evangelou AI, Ignatchenko A, Agochiya M, Brown TJ, Ringuette MJ, Jurisica I, Kislinger T. Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT). Mol Biosyst 2008, 4:762-773. 10.1039/b717542f, 18563251.
33. Tilghman RW, Blais EM, Cowan CR, Sherman NE, Grigera PR, Jeffery ED, Fox JW, Blackman BR, Tschumperlin DJ, Papin JA, Parsons JT. Matrix rigidity regulates cancer cell growth by modulating cellular metabolism and protein synthesis. PLoS One 2012, 7:e37231. 10.1371/journal.pone.0037231, 3356407, 22623999.
34. Chen Y, Lu B, Yang Q, Fearns C, Yates JR, Lee JD. Combined integrin phosphoproteomic analyses and small interfering RNA-based functional screening identify key regulators for cancer cell adhesion and migration. Cell Res 2009, 69:3713-3720.
35. Jin L, Zhang Y, Li H, Yao L, Fu D, Yao X, Xu LX, Hu X, Hu G. Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis. Cell Res 2012, 22:1356-1373. 10.1038/cr.2012.90, 3434352, 22688893.
36. Stellas D, Patsavoudi E. Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment. Anticancer Agents Med Chem 2012, 12:707-717. 10.2174/187152012802650246, 22292747.
37. Voura EB, English JL, Yu HY, Ho AT, Subarsky P, Hill RP, Hojilla CV, Khokha R. Proteolysis during tumor cell extravasation in vitro: metalloproteinase involvement across tumor cell types. PLoS One 2013, 8:e78413. 10.1371/journal.pone.0078413, 3806793, 24194929.
38. Poincloux R, Lizarraga F, Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci 2009, 122:3015-3024. 10.1242/jcs.034561, 19692588.
39. Niiya D, Egawa N, Sakamoto T, Kikkawa Y, Shinkawa T, Isobe T, Koshikawa N, Seiki M. Identification and characterization of Lutheran blood group glycoprotein as a new substrate of membrane-type 1 matrix metalloproteinase 1 (MT1-MMP): a systemic whole cell analysis of MT1-MMP-associating proteins in A431 cells. J Biol Chem 2009, 284:27360-27369. 10.1074/jbc.M109.029124, 2785664, 19667067.
40. Tam EM, Morrison CJ, Wu YI, Stack MS, Overall CM. Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc Natl Acad Sci U S A 2004, 101:6917-6922. 10.1073/pnas.0305862101, 406442, 15118097.
41. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004, 6:507-514. 10.1038/ncb1131, 15146192.
42. Bok RA, Hansell EJ, Nguyen TP, Greenberg NM, McKerrow JH, Shuman MA. Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model. Prostate Cancer Prostatic Dis 2003, 6:272-280. 10.1038/sj.pcan.4500676, 14663466.
43. Beliveau A, Mott JD, Lo A, Chen EI, Koller AA, Yaswen P, Muschler J, Bissell MJ. Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes Dev 2010, 24:2800-2811. 10.1101/gad.1990410, 3003198, 21159820.
44. Burns JS, Kristiansen M, Kristensen LP, Larsen KH, Nielsen MO, Christiansen H, Nehlin J, Andersen JS, Kassem M. Decellularized matrix from tumorigenic human mesenchymal stem cells promotes neovascularization with galectin-1 dependent endothelial interaction. PLoS One 2011, 6:e21888. 10.1371/journal.pone.0021888, 3133605, 21779348.
45. Li MX, Xiao ZQ, Chen YH, Peng F, Li C, Zhang PF, Li MY, Li F, Duan CJ, Li DJ, Yao HX, Chen ZC. Proteomic analysis of the stroma-related proteins in nasopharyngeal carcinoma and normal nasopharyngeal epithelial tissues. Med Oncol 2010, 27:134-144. 10.1007/s12032-009-9184-1, 19242827.
46. Sheehan KM, Gulmann C, Eichler GS, Weinstein JN, Barrett HL, Kay EW, Conroy RM, Liotta LA, Petricoin EF. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene 2008, 27:323-331. 10.1038/sj.onc.1210647, 17621268.
47. Fleming JM, Miller TC, Quinones M, Xiao Z, Xu X, Meyer MJ, Ginsburg E, Veenstra TD, Vonderhaar BK. The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo. BMC Med 2010, 8:27. 10.1186/1741-7015-8-27, 2894739, 20492690.
48. Wehr AY, Furth EE, Sangar V, Blair IA, Yu KH. Analysis of the human pancreatic stellate cell secreted proteome. Pancreas 2011, 40:557-566. 10.1097/MPA.0b013e318214efaf, 3086313, 21499210.
49. Trimmer C, Sotgia F, Whitaker-Menezes D, Balliet RM, Eaton G, Martinez-Outschoorn UE, Pavlides S, Howell A, Iozzo RV, Pestell RG, Scherer PE, Capozza F, Lisanti MP. Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Cancer Biol Ther 2011, 11:383-394. 10.4161/cbt.11.4.14101, 3047109, 21150282.
50. Hemers E, Duval C, McCaig C, Handley M, Dockray GJ, Varro A. Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: implications for epithelial-mesenchymal signaling. Cancer Res 2005, 65:7363-7369. 10.1158/0008-5472.CAN-05-0157, 16103088.
51. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, Srinivasan R, Trimboli AJ, Martin CK, Li F, Yu L, Fernandez SA, Pécot T, Rosol TJ, Cory S, Hallett M, Park M, Piper MG, Marsh CB, Yee LD, Jimenez RE, Nuovo G, Lawler SE, Chiocca EA, Leone G, Ostrowski MC. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol 2012, 14:159-167.
52. Newman AC, Nakatsu MN, Chou W, Gershon PD, Hughes CC. The requirement for fibroblasts in angiogenesis: fibroblast-derived matrix proteins are essential for endothelial cell lumen formation. Mol Biol Cell 2011, 22:3791-3800. 10.1091/mbc.E11-05-0393, 3192859, 21865599.
53. Hawsawi NM, Ghebeh H, Hendrayani SF, Tulbah A, Al-Eid M, Al-Tweigeri T, Ajarim D, Alaiya A, Dermime S, Aboussekhra A. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res 2008, 68:2717-2725. 10.1158/0008-5472.CAN-08-0192, 18413739.
54. Zhong L, Roybal J, Chaerkady R, Zhang W, Choi K, Alvarez CA, Tran H, Creighton CJ, Yan S, Strieter RM, Pandey A, Kurie JM. Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res 2008, 68:7237-7245. 10.1158/0008-5472.CAN-08-1529, 2562343, 18757440.
55. Holmberg C, Quante M, Steele I, Kumar JD, Balabanova S, Duval C, Czepan M, Rakonczay Z, Tiszlavicz L, Nemeth I, Lazar G, Simonka Z, Jenkins R, Hegyi P, Wang TC, Dockray GJ, Varro A. Release of TGFbetaig-h3 by gastric myofibroblasts slows tumor growth and is decreased with cancer progression. Carcinogenesis 2012, 33:1553-1562. 10.1093/carcin/bgs180, 3499060, 22610072.
56. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010, 16:483-489. 10.1038/nm.2112, 3786785, 20228816.
57. Shekhar MP, Santner S, Carolin KA, Tait L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol 2007, 170:1546-1560. 10.2353/ajpath.2007.061004, 1854950, 17456761.
58. Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, Frei E. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990, 247:1457-1461. 10.1126/science.2108497, 2108497.
59. Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2009, 15:6630-6638. 10.1158/1078-0432.CCR-09-1001, 19843665.
60. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504. 10.1038/nature11183, 3711467, 22763439.
61. Alcolea S, Antón R, Camacho M, Soler M, Alfranca A, Avilés-Jurado FX, Redondo JM, Quer M, León X, Vila L. Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE2. J Lipid Res 2012, 53:630-642. 10.1194/jlr.M019695, 3307640, 22308510.
62. Karagiannis GS, Petraki C, Prassas I, Saraon P, Musrap N, Dimitromanolakis A, Diamandis EP. Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. Oncotarget 2012, 3:267-285. 3359884, 22408128.
63. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006, 1:119-150. 10.1146/annurev.pathol.1.110304.100224, 18039110.
64. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217. 10.1016/j.ccr.2005.02.013, 15766659.
65. Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, Marques MB, Monestier M, Toy P, Werb Z, Looney MR. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 2012, 122:2661-2671. 10.1172/JCI61303, 3386815, 22684106.
66. van Kempen LC, de Visser KE, Coussens LM. Inflammation, proteases and cancer. Eur J Cancer 2006, 42:728-734. 10.1016/j.ejca.2006.01.004, 16524717.
67. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006, 27:1086-1095. 10.1183/09031936.06.00135305, 16540497.
68. Kobayashi R, Deavers M, Patenia R, Rice-Stitt T, Halbe J, Gallardo S, Freedman RS. 14-3-3 zeta protein secreted by tumor associated monocytes/macrophages from ascites of epithelial ovarian cancer patients. Cancer Immunol Immunother 2009, 58:247-258. 10.1007/s00262-008-0549-7, 18618111.
69. Aller MA, Arias JL, Nava MP, Arias J. Posttraumatic inflammation is a complex response based on the pathological expression of the nervous, immune, and endocrine functional systems. Exp Biol Med (Maywood) 2004, 229:170-181.
70. Lichtenfels R, Mougiakakos D, Johansson CC, Dressler SP, Recktenwald CV, Kiessling R, Seliger B. Comparative expression profiling of distinct T cell subsets undergoing oxidative stress. PLoS One 2012, 7:e41345. 10.1371/journal.pone.0041345, 3401147, 22911781.
71. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006, 176:284-290.
72. Chornoguz O, Grmai L, Sinha P, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S. Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Mol Cell Proteomics 2011, 10:M110.002980. 10.1074/mcp.M110.002980, 3047151, 21191032.
73. Li X, Ni R, Chen J, Liu Z, Xiao M, Jiang F, Lu C. The presence of IGHG1 in human pancreatic carcinomas is associated with immune evasion mechanisms. Pancreas 2011, 40:753-761. 10.1097/MPA.0b013e318213d51b, 21654544.
74. Venugopal C, Wang XS, Manoranjan B, McFarlane N, Nolte S, Li M, Murty N, Siu KW, Singh SK. GBM secretome induces transient transformation of human neural precursor cells. J Neurooncol 2012, 109:457-466. 10.1007/s11060-012-0917-1, 22752853.
75. Fukaya Y, Shimada H, Wang LC, Zandi E, DeClerck YA. Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J Biol Chem 2008, 283:18573-18581. 10.1074/jbc.M803115200, 18450743.
76. Yu L, Shi J, Cheng S, Zhu Y, Zhao X, Yang K, Du X, Klocker H, Yang X, Zhang J. Estrogen promotes prostate cancer cell migration via paracrine release of ENO1 from stromal cells. Mol Endocrinol 2012, 26:1521-1530. 10.1210/me.2012-1006, 22734040.
77. Celis JE, Moreira JM, Cabezón T, Gromov P, Friis E, Rank F, Gromova I. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol Cell Proteomics 2005, 4:492-522. 10.1074/mcp.M500030-MCP200, 15695426.
78. Belletti B, Vaidya JS, D'Andrea S, Entschladen F, Roncadin M, Lovat F, Berton S, Perin T, Candiani E, Reccanello S, Veronesi A, Canzonieri V, Trovò MG, Zaenker KS, Colombatti A, Baldassarre G, Massarut S. Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res 2008, 14:1325-1332. 10.1158/1078-0432.CCR-07-4453, 18316551.
79. Cohen A, Wang E, Chisholm KA, Kostyleva R, O'Connor-McCourt M, Pinto DM. A mass spectrometry-based plasma protein panel targeting the tumor microenvironment in patients with breast cancer. J Proteomics 2013, 81:135-147.
80. Kadowaki M, Sangai T, Nagashima T, Sakakibara M, Yoshitomi H, Takano S, Sogawa K, Umemura H, Fushimi K, Nakatani Y, Nomura F, Miyazaki M. Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach. J Cancer Res Clin Oncol 2011, 137:1105-1115. 10.1007/s00432-010-0974-9, 21253761.
81. Kang S, Maeng H, Kim BG, Qing GM, Choi YP, Kim HY, Kim PS, Kim Y, Kim YH, Choi YD, Cho NH. In situ identification and localization of IGHA2 in the breast tumor microenvironment by mass spectrometry. J Proteome Res 2012, 11:4567-4574. 10.1021/pr3003672, 22894699.
82. Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 2013, 42:193-197. 10.1097/MPA.0b013e31825e354d, 23407481.
83. Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Buson TB, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA, Nelson PS, Hanash SM, Kemp CJ. Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 2011, 71:5090-5100. 10.1158/0008-5472.CAN-11-0568, 3148311, 21653680.
84. Gomes C, Almeida A, Ferreira JA, Silva L, Santos-Sousa H, Pinto-de-Sousa J, Santos LL, Amado F, Schwientek T, Levery SB, Mandel U, Clausen H, David L, Reis CA, Osório H. Glycoproteomic analysis of serum from patients with gastric precancerous lesions. J Proteome Res 2013, 12:1454-1466. 10.1021/pr301112x, 23312025.
85. Chen HL, Seol H, Brown KJ, Gordish-Dressman H, Hill A, Gallo V, Packer R, Hathout Y. Secretome survey of human plexiform neurofibroma derived Schwann cells reveals a secreted form of the RARRES1 protein. Int J Mol Sci 2012, 13:9380-9399. 10.3390/ijms13079380, 3430302, 22942771.
86. Li M, Li C, Li D, Xie Y, Shi J, Li G, Guan Y, Li M, Zhang P, Peng F, Xiao Z, Chen Z. Periostin, a stroma-associated protein, correlates with tumor invasiveness and progression in nasopharyngeal carcinoma. Clin Exp Metastasis 2012, 29:865-877. 10.1007/s10585-012-9465-5, 22706927.
87. Kamper P, Ludvigsen M, Bendix K, Hamilton-Dutoit S, Rabinovich GA, Møller MB, Nyengaard JR, Honoré B, D'Amore F. Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood 2011, 117:6638-6649. 10.1182/blood-2010-12-327346, 21505194.
88. Teng PN, Hood BL, Sun M, Dhir R, Conrads TP. Differential proteomic analysis of renal cell carcinoma tissue interstitial fluid. J Proteome Res 2011, 10:1333-1342. 10.1021/pr101074p, 21142074.
89. Bijian K, Mlynarek AM, Balys RL, Jie S, Xu Y, Hier MP, Black MJ, Di Falco MR, LaBoissiere S, Alaoui-Jamali MA. Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment. J Proteome Res 2009, 8:2173-2185. 10.1021/pr800979e, 19284786.
90. Li Y, Li Y, Chen T, Kuklina AS, Bernard P, Esteva FJ, Shen H, Ferrari M, Hu Y. Circulating proteolytic products of carboxypeptidase N for early detection of breast cancer. Clin Chem 2014, 60:233-242. 10.1373/clinchem.2013.211953, 24146311.
91. Bernhard OK, Greening DW, Barnes TW, Ji H, Simpson RJ. Detection of cadherin-17 in human colon cancer LIM1215 cell secretome and tumour xenograft-derived interstitial fluid and plasma. Biochim Biophys Acta 1834, 2013:2372-2379.